Telomir Pharmaceuticals Announces Upcoming Clinical Trials for Telomir-1, Aiming to Tackle Aging and Rare Diseases

Reuters
06-02
<a href="https://laohu8.com/S/TELO">Telomir Pharmaceuticals</a> Announces Upcoming Clinical Trials for Telomir-1, Aiming to Tackle Aging and Rare Diseases

Telomir Pharmaceuticals Inc. (Nasdaq: TELO) has announced its participation in the upcoming BIO International Convention 2025 in Boston, Massachusetts, scheduled from June 16-19, 2025. The company plans to engage in BIO One-on-One Partnering™ meetings to explore potential licensing, strategic collaborations, and M&A opportunities. Additionally, Telomir provided updates on its lead candidate, Telomir-1, which is designed to elongate telomeres, regenerate cells, and address key drivers of biological aging. The company is preparing for an Investigational New Drug $(IND.AU)$ submission by the end of the year and anticipates initiating first-in-human clinical trials in the first half of 2026. Telomir also reported preclinical progress in areas such as retinal regeneration, lifespan extension, Type 2 diabetes reversal, and anti-cancer effects. Furthermore, Telomir is launching a rare disease development initiative targeting conditions like Werner's syndrome, Wilson's disease, Progeria, and dysphonia.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Telomir Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001641172-25-013196), on June 02, 2025, and is solely responsible for the information contained therein.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10